SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer

European Journal of Cancer

Volumn 48, Issue 13, 2012, Pages 1988-1996

  Knappskog, Stian ^a,b   Trovik, Jone ^a,b   Marcickiewicz, Janusz ^c   Tingulstad, Solveig ^d   Staff, Annetine C ^e,f   Romundstad, Pl ^g   Hveem, Kristian ^g   Vatten, Lars ^g   Salvesen, Helga B ^a,b   Lønning, Per E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Endometrial cancer; MDM2; Oestrogen; Polymorphism; Prostatic cancer

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN MDM2; TRANSCRIPTION FACTOR SP1;

AGED; ARTICLE; BINDING SITE; BREAST CANCER; CANCER PATIENT; CANCER RISK; COMPUTER MODEL; CONTROLLED STUDY; ENDOMETRIUM CANCER; EXON; FEMALE; GENDER; GENETIC ASSOCIATION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OVARY CANCER; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BINDING SITES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ESTROGEN; RISK; SEX FACTORS; SP1 TRANSCRIPTION FACTOR;

EID: 84860459353     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.024     Document Type: Article

References (33)

1. Y. Haupt, R. Maya, and A. Kazaz Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299 (Pubitemid 27220766)
2. R. Honda, H. Tanaka, and H. Yasuda Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 FEBS Lett. 420 1997 25 27 (Pubitemid 28037193)
3. M.H. Kubbutat, S.N. Jones, and K.H. Vousden Regulation of p53 stability by Mdm2 Nature 387 1997 299 303 (Pubitemid 27220767)
4. A. Bouska, and C.M. Eischen Mdm2 affects genome stability independent of p53 Cancer Res. 69 2009 1697 1701
5. F. Toledo, and G.M. Wahl Regulating the p53 pathway: in vitro hypotheses, in vivo veritas Nat Rev Cancer 6 2006 909 923 (Pubitemid 44862676)
6. J.D. Oliner, K.W. Kinzler, and P.S. Meltzer Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 358 1992 80 83
7. J. Momand, D. Jung, and S. Wilczynski The MDM2 gene amplification database Nucleic Acids Res. 26 1998 3453 3459 (Pubitemid 28347214)
8. F. Bartel, A. Meye, and P. Wurl Amplification of the MDM2 gene, but not expression of splice variants of MDM2 mRNA, is associated with prognosis in soft tissue sarcoma Int J Cancer 95 2001 168 175 (Pubitemid 32477232)
9. G.L. Bond, W. Hu, and E.E. Bond A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 2004 591 602 (Pubitemid 39535748)
10. G.L. Bond, K.M. Hirshfield, and T. Kirchhoff MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 66 2006 5104 5110 (Pubitemid 43844932)
11. GL. Bond, C. Menin, and R. Bertorelle MDM2 SNP309 Accelerates colorectal tumour formation in women J Med Genet 43 2006 950 952 (Pubitemid 46080193)
12. K.P. Economopoulos, and T.N. Sergentanis Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race. a meta-analysis Breast Cancer Res Treat 120 2010 211 216
13. Z. Hu, G. Jin, and L. Wang MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies Cancer Epidemiol Biomarkers Prev 16 2007 2717 2723 (Pubitemid 351196328)
14. S. Knappskog, M. Bjornslett, and L.M. Myklebust The MDM2 Promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians Cancer Cell 19 2011 273 282
15. S. Knappskog, and P.E. Lonning MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk Oncotarget 2 2011 251 258
16. S.J. Neo, X. Su, and J.S. Thomsen Surface plasmon resonance study of cooperative interactions of estrogen receptor alpha and transcriptional factor Sp1 with composite DNA elements Anal Chem 81 2009 3344 3349
17. D. Sisci, E. Middea, and C. Morelli 17beta-estradiol enhances alpha(5) integrin subunit gene expression through ERalpha-Sp1 interaction and reduces cell motility and invasion of ERalpha-positive breast cancer cells Breast Cancer Res Treat 124 2010 63 77
18. A. Suzuki, N. Sanda, and Y. Miyawaki Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex J Biol Chem 285 2010 13444 13453
19. J. Trovik, E. Wik, and I.M. Stefansson Stathmin overexpression identifies high risk patients and lymph node metastasis in endometrial cancer Clin Cancer Res 17 2011 3368 3377
20. A. Sandelin, W. Alkema, and P. Engstrom JASPAR: an open-access database for eukaryotic transcription factor binding profiles Nucleic Acids Res 32 2004 D91 D94
21. H.K. Kinyamu, and T.K. Archer Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression Mol Cell Biol 23 2003 5867 5881 (Pubitemid 36951348)
22. L.S. Ulrich Endometrial cancer, types, prognosis, female hormones and antihormones Climacteric 14 2011 418 425
23. S.P. Balk, and K.E. Knudsen AR, the cell cycle, and prostate cancer Nucl Recept Signal 6 2008 e001
24. O. Nunobiki, M. Ueda, and M. Yamamoto Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer Hum Cell 22 2009 101 106
25. K. Terry, M. McGrath, and I.M. Lee MDM2 SNP309 is associated with endometrial cancer risk Cancer Epidemiol Biomarkers Prev 17 2008 983 986 (Pubitemid 351536433)
26. M. Ueda, M. Yamamoto, and O. Nunobiki Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer Hum Cell 22 2009 49 54
27. C.S. Walsh, C.W. Miller, and B.Y. Karlan Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk Gynecol Oncol 104 2007 660 664
28. K.A. Ashton, A. Proietto, and G. Otton Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer Gynecol Oncol 113 2009 109 114
29. D. Krekac, K. Brozkova, and D. Knoflickova MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk Oncology 74 2008 84 87 (Pubitemid 351915014)
30. R. Stoehr, F. Hitzenbichler, and B. Kneitz Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics Br J Cancer 99 2008 78 82 (Pubitemid 351920239)
31. X. Bin, Z. Xu, and G. Cheng Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese Cancer Genet Cytogenet 202 2010 76 81
32. T. Sun, G.S. Lee, and W.K. Oh Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population Clin Cancer Res 16 2010 5244 5251
33. L. Sucheston, D.B. Witonsky, and D. Hastings Natural selection and functional genetic variation in the p53 pathway Hum Mol Genet 20 2011 1502 1508